Roytberg GE¹, Plotkin M² and Sharkhun OO¹*

¹Pirogov Russian National Research Medical University, Moscow, Russia
²The Vivantes Institute for Nuclear Medicine, Berlin, Germany

*Corresponding Author: Roytberg GE, Pirogov Russian National Research Medical University, Moscow, Russia.

Received: March 14, 2022; Published: June 20, 2022

Abstract

Despite the improvement of diagnostic methods and the introduction of prostate-specific antigen monitoring, the incidence of advanced forms of prostate cancer in Russia remains high. Long-term hormonal therapy often leads to tumor adaptation and further progression of the disease, the development of castrate-resistant prostate cancer, the complications of which significantly worsen the quality of life and adversely affect overall survival rates. Over the past 3 years along with the introduction into clinical practice of numerous drugs for the treatment of such forms of the disease, new types of palliative peptide receptor radionuclide therapy have been developed in particular, using the isotopes Lutetium-177, Radium-223, Actinium-225 etc. Currently therapy with ¹⁷⁷Lu -PSMA is experimental in nature, as the drug has not yet been approved for clinical use by either European or American drug control agencies. However, the results of studies published to date are encouraging for the future clinical applications of ¹⁷⁷Lu-PSMA therapy. The results of prospective studies conducted in the last 2-3 years will be crucial for the future of this method.

Keywords: Prostate; Cancer; Radionuclide; Lutetium

References

1. Freedland SJ., et al. “Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices”. Urology2 (2012): 293-298.
2. Tait C., et al. “Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival”. BJU International6b (2014): E70-E73.
3. Israeli RS., et al. “Expression of the prostate-specific membrane antigen”. Cancer Research7 (1994): 1807-1811.
4. Benešová M. “Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer”. Journal of Nuclear Medicine 56 (2015): 914-920.
5. Kratochwil C., et al. “177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer”. European Journal of Nuclear Medicine and Molecular Imaging 42 (2015): 987-988.
6. Ahmadzadehfar H., et al. “Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study”. EJNMMI Research 5 (2015): 1140259-014-2978-1.
7. Delker A., et al. “Dosimetry for (177)Lu-DKFZPSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer”. European Journal of Nuclear Medicine and Molecular Imaging 4 (2016): 42-51.
8. Rahbar K., et al. “German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients”. Journal of Nuclear Medicine 58 (2017): 85-90.
9. Hofman MS., et al. “TheraP: a randomized phase 2 trial of ¹⁷⁷Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)”. BJU International 124 (2019): 5-13.
10. Weineisen M., et al. “68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies”. Journal of Nuclear Medicine8 (2015): 1169-1176.
11. Morris MJ., et al. “Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)”. ASCO (2021).
12. de Bono J., et al. “Olaparib for Metastatic Castration-Resistant Prostate Cancer”. The New England Journal of Medicine 22 (2020): 2091-2102.
13. Kratochwil C., et al. “ (²²⁵)Ac-PSMA-617 for Therapy of Prostate Cancer”. Seminars in Nuclear Medicine 2 (2019): 133-140.
14. Khreish F., et al. “²²⁵Ac-PSMA-617/¹⁷⁷Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience”. European Journal of Nuclear Medicine and Molecular Imaging 3 (2020): 721-728.
15. S3-Leitlinie Prostatakarzinom (leitlinienprogramm-onkologie.de) Version 6.0 | Mai (2021).
16. Kratochwil C., et al. “EANM procedure guidelines for radionuclide therapy with ¹⁷⁷Lu-labelled PSMA-ligands (¹⁷⁷Lu-PSMA-RLT)”. European Journal of Nuclear Medicine and Molecular Imaging12 (2019): 2536-2544.
17. EAU-EANM-ESTRO-ESUR-SIOG-Guidelines-on-Prostate-Cancer-2020 v4.pdf (uroweb.org)
18. Lowrance WT., et al. “Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II”. Journal of Urology 205 (2021): 22-29.
19. Khalaf DJ., et al. “Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial”. Lancet Oncology12 (2019): 1730-1739.

Citation

Citation: Roytberg GE., et al. “Prospects for the Clinical Use of Radionuclide Therapy for Castrate-resistant Metastatic Prostate Cancer with ¹⁷⁷Lu-PSMA”.Acta Scientific Medical Sciences 6.7 (2022): 179-183.

Copyright

Copyright: © 2022 Roytberg GE., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.